Table I. Effect of cortistatin in chronic progressive EAE and remitting and relapsing EAE
Incidence (%)a
NoneMildModerateSevereMortalityCDIb
CP-EAE
 Control1/19 (5%)1/19 (5%)5/19 (27%)12/19 (63%)12/19 (63%)97.9 ± 11.2
 Cortistatin9/18 (59%)4/18 (22%)3/18 (17%)2/18 (11%)0/18 (0%)34.0 ± 6.1**
RR-EAE
 Control0/8 (0%)0/8 (0%)4/8 (50%)4/8 (50%)1/8 (12%)38.4 ± 8.4
 Cortistatin5/8 (62%)3/8 (37%)0/8 (0%)0/8 (0%)0/8 (0%)20.5 ± 6.6*
  • Chronic progressive EAE (CP-EAE) was induced in C57BL/6 mice by immunization with MOG35–55, and relapsing and remitting EAE (RR-EAE) was induced in SJL/J mice by immunization with PLP139–151. Immunized mice were treated i.p. for 5 d with PBS (control) or with cortistatin (1 nmol/day) starting at the onset of clinical signs (clinical score, 1). n = 3 independent experiments for CP-EAE; n = 1 experiment for RR-EAE.

  • a Disease incidence is graded as severe (clinical score, >4), moderate (clinical score, 2–4), mild (clinical score, <2), or none (no clinical signs) at day 36 for CP-EAE and at day 50 for RR-EAE.

  • b Clinical disease index (CDI), the mean of the sum of the daily disease scores.

  • * p < 0.005, **p < 0.0001 versus control.